Development and quality control studies of radiolabelled nanostructured lipid formulations with Ga-68

This study aims to radiolabel a nanoparticle formulation containing donepezil with Ga-68 radionuclide with high efficiency for diagnosing Alzheimer's disease. In order to develop lipid carrier systems with biocompatible contents in nanoparticle structures, extensive formulation studies were conducted. These systems were subsequently radiolabeled with Ga-68 radionuclide to evaluate their radiolabeling efficiencies. The results are highly encouraging, suggesting that effective radiolabeling is indeed possible. These findings are particularly significant as they open up a range of applications for targeted drug delivery, medical imaging, and diagnostics. Overall, this study represents a valuable contribution to the expanding body of knowledge on lipid carrier systems in healthcare.

Nanocarrier formulations were prepared. The radiolabeling parameters of the prepared formulations were studied comparatively. A Ga-68 radionuclide with a half-life of 68 min was used for this. Incubation time, amount of radioactivity, and pH parameters were studied.

The radiolabeling incubation time, pH of the experimental medium, and amount of radioactivity were tested, and the optimal parameters were identified. According to the results of the radiolabeling studies, optimal radiolabeling with Ga-68 radionuclide was obtained in an acid medium (pH: 5), with a 60 min incubation time, and using 5 mCi of activity in the DOTA-functionalized nanolipid formulations, achieving 89.17 % efficiency. Furthermore, quantitative in vivo PET/CT imaging in nude mice (n = 3/group) demonstrated that the optimized Ga-68-DNP-NLC formulation achieved statistically significant and higher brain uptake compared to the free Ga-68 control, confirming its ability to cross the blood-brain barrier.